Venous thromboembolism (VTE), in particular acute pulmonary embolism (PE), has been shown to be a frequent and potentially fatal complication of coronavirus disease 2019 (COVID-19). In response to the observed thrombotic complications, a large number of studies has been devoted to the understanding and management of COVID-19-associated coagulopathy. Notably, only a limited number of mostly retrospective studies has focused on the optimal diagnostic strategy for suspected PE in COVID-19 patients. As in other special populations, the accuracy of diagnostic algorithms for PE-exclusion has been debated in this specific patient subgroup as the specificity of D-dimer assays and clinical decision rules (CDRs) may be lower than normal. From this viewpoint, we discuss the current state-of-the-art diagnostic algorithms for acute PE with a focus on patients with COVID-19 in the perspective of other special patient populations. Furthermore, we summarize current knowledge regarding the natural history of PE resolution with anticoagulant treatment in patients with COVID-19.
Evidence on how diagnostic algorithms perform in patients with prior venous thromboembolism (VTE) is scarce. This study determined the diagnostic miss rate during 3-month follow-up and the proportion of avoided imaging using the YEARS and Pulmonary Embolism Graduated D-dimer (PEGeD) algorithms. This preplanned analysis was part of the international prospective multicenter PREDICTORS study that included outpatients suspected of recurrent VTE managed with validated diagnostic algorithms and D-dimer assays per local practices. Clinical variables were collected to compute the original Wells, modified Wells, and revised Geneva scores. Patients without VTE were followed up for 3 months. Events were independently adjudicated. For this analysis, YEARS and PEGeD scores were computed post hoc for patients with suspected pulmonary embolism (PE). In total, 188 patients were included. Overall, PE incidence at baseline was 31% (58/188), and 47% (47/99) in those without anticoagulation. Applying YEARS, 87 patients (46%) would have had PE ruled out without imaging. The overall diagnostic miss rate would have been 2 of 83 (2.4%; 95% CI, 0.7%-8.4%) and 2 of 29 (6.9%; 95% CI, 1.9%-22%) in those without anticoagulation: both patients had no YEARS items and D-dimer of <1000 ng/mL but had imaging at baseline showing PE. For PEGeD, these numbers were 80 (43%) for efficiency, with an associated diagnostic miss rate of 2 of 77 (2.6%; 95% CI, 0.7%-9.0%) and 2 of 26 (7.7%; 95% CI, 2.1%-24%) in those without anticoagulation: both patients had a Wells score of <4.5 and D-dimer of <1000 ng/mL but had imaging at baseline showing PE. Both diagnostic algorithms showed comparable safety and efficiency in patients with prior VTE. Notably, the diagnostic miss rate was higher than expected and exceeded the safety margin.
Background: Pulmonary embolism (PE) is frequently suspected in patients with cancer due to non-specific symptoms suggestive of PE and their inherent risk of venous thromboembolism (VTE). Commonly used clinical decision rules (CDRs) and D-dimer testing may be less reliable in this specific population. Due to the lack of guideline recommendations on the optimal diagnostic approach and the perceived futility of D-dimer in patients with cancer, clinicians often use computed tomography pulmonary angiography (CTPA) as a sole diagnostic test. This practice exposes patients to potentially unnecessary radiation and harm, and contributes to a significant burden on healthcare systems through inefficient resource allocation. The YEARS algorithm is an easy-to-use CDR that has been shown to safely exclude PE without the need for CTPA in a diverse population of patients with suspected PE. Objective: To compare the safety and efficiency of the YEARS algorithm to the safety and efficiency of CTPA only in the diagnostic management of acute PE in cancer patients. Design and interventions: The Hydra study (ClinicalTrials.gov NCT04657120 ) is an investigator-initiated, multicentre, multinational open-label, randomised, non-inferiority trial with blinded adjudication of outcome events, comparing the YEARS algorithm with CTPA only in the diagnostic work-up of cancer patients with clinically suspected acute PE. Participants are randomised in a 1:1 ratio to each diagnostic strategy via a web-based system. The trial anticipates to include 1566 patients. Participants: Consecutive patients with active cancer who are hospitalized or present to the emergency department, outpatient clinic, or thrombosis clinic with clinically suspected PE and who are not receiving therapeutic anticoagulation or have an indication for anticoagulation therapy other than PE. Study outcomes: The primary safety outcome is the proportion of symptomatic and objectively proven fatal or non-fatal VTE (i.e., PE or deep vein thrombosis in the upper or lower extremities) or death with undetermined cause where acute PE could not be ruled out as contributing factor during three months follow-up in patients in whom PE was ruled out at initial testing. The primary efficiency outcome is the proportion of negative CTPA scans for PE, relative to the total number of CTPA scans performed at initial testing.